<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652014</url>
  </required_header>
  <id_info>
    <org_study_id>021002</org_study_id>
    <secondary_id>NCI-2011-03187</secondary_id>
    <secondary_id>0220100266</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <nct_id>NCT01652014</nct_id>
  </id_info>
  <brief_title>Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and applicability of experimental forms of umbilical&#xD;
      cord blood (UCB) transplantation for patients with high risk hematologic malignancies who&#xD;
      might benefit from a hematopoietic stem cell transplant (HSCT) but who do not have a standard&#xD;
      donor option (no available HLA-matched related donor (MRD), HLA-matched unrelated donor&#xD;
      (MUD)), or single UCB unit with adequate cell number and HLA-match).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding unavailable&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment of white blood cells (WBC) (absolute neutrophil count &gt; 500/mm^3)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>40 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment rate (non-transfusion dependent)</measure>
    <time_frame>At 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of infection requiring hospitalization or prolongation of hospitalization</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of steroid-refractory acute GVHD</measure>
    <time_frame>at 100 days</time_frame>
    <description>GVHD will be staged per standard guidelines of the American Society for Blood and Bone Marrow Transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of extensive chronic GVHD</measure>
    <time_frame>up to 2 years</time_frame>
    <description>GVHD will be staged per standard guidelines of the American Society for Blood and Bone Marrow Transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time on immunosuppressive therapy</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CD4 count &gt; 200/mm^3</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncutaneous Extranodal Lymphoma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>T-cell Large Granular Lymphocyte Leukemia</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double UCB transplantation&#xD;
Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub-threshold single UCB + irradiated PBMCs transplantation&#xD;
Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV over 1 hour on Day -6; after pre-hydration</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV daily over 30 minutes for 5 days (Days -6 to -2)</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO 1.0 g BID Day 1-30</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo double-unit allogeneic UCB transplant</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>Undergo single allogeneic UCB transplant</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>cord blood transplantation</other_name>
    <other_name>transplantation, umbilical cord blood</other_name>
    <other_name>UCB transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>double-unit umbilical cord blood transplantation</intervention_name>
    <description>Undergo double-unit allogeneic UCB transplant</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo single allogeneic UCB transplant</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo irradiated allogeneic peripheral blood stem cell transplant</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven hematologic malignancy with anticipated 2 year&#xD;
             survival &lt; 20% with standard therapy; patients age &lt;18 are excluded by virtue of the&#xD;
             policies and procedures of the allogeneic hematopoietic stem cell transplant (HSCT)&#xD;
             program (Cancer Institute of New Jersey [CINJ]/Robert Wood Johnson University Hospital&#xD;
             [RWJUH] is not an approved Pediatric Transplant Center); patients &gt; age 65 are&#xD;
             generally not considered candidates for experimental unrelated allogeneic HSCT, as&#xD;
             utilized in this study by virtue of the anticipated delayed immune reconstitution,&#xD;
             high risk of GVHD, and known negative impact of age on outcomes&#xD;
&#xD;
          -  Patients eligible for this trial will have high risk diseases that include, but are&#xD;
             not limited to:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) in second complete remission (CR2) or greater or&#xD;
                  early relapse with &lt; 5% marrow blasts and no circulating blasts&#xD;
&#xD;
               -  AML in first complete remission (CR1) with high risk cytogenetics (complex,&#xD;
                  monosomy 5, monosomy 7, 11q23 (not t(9;11)), t(6;9), chromosome 3, monosomy&#xD;
                  phenotype and other karyotypes estimated to have =&lt; 20% disease free survival at&#xD;
                  3 years) or secondary/transformed AML without favorable cytogenetics;&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL) with t(9;22), 11q23 abnormality or early&#xD;
                  relapse (&lt; 5% marrow blasts) or CR2 or greater;&#xD;
&#xD;
               -  Chronic myeloid leukemia (CML) resistant/refractory to all commercially available&#xD;
                  Abelson (abl) kinase inhibitors (e.g. imatinib mesylate, dasatinib, nilotinib) or&#xD;
                  predicted to be so based upon clinical course or abl kinase domain mutation&#xD;
                  analysis; or in accelerated phase or blast crisis;&#xD;
&#xD;
               -  High intermediate to high international prognostic score myelodysplasia;&#xD;
&#xD;
               -  Non-Hodgkin lymphoma (NHL)/Hodgkin lymphoma (HL)/other lymphoproliferative&#xD;
                  diseases resistant/refractory to standard therapies and for whom an autologous&#xD;
                  transplant is considered to be inappropriate (e.g. bone marrow involvement,&#xD;
                  chemotherapy refractory disease, prior transplant);&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL) resistant/refractory to standard therapies&#xD;
                  (e.g. fludarabine) or high risk cytogenetics/fluorescence in situ hybridization&#xD;
                  (FISH) (e.g. 17p-);&#xD;
&#xD;
               -  Myeloproliferative disorders with progressive disease or cytopenias or clinical&#xD;
                  symptoms refractory to standard therapy (e.g. hypomethylating agents)&#xD;
&#xD;
               -  Relapsed or refractory multiple myeloma after (or not eligible for) high dose&#xD;
                  chemotherapy/autologous hematopoietic stem cell rescue and following salvage&#xD;
                  therapy with thalidomide, lenalidomide or bortezomib/other Food and Drug&#xD;
                  Administration (FDA)-approved multiple myeloma salvage therapies;&#xD;
&#xD;
               -  Other hematologic malignancies/disorders with anticipated 2 year survival &lt; 20%,&#xD;
                  as established by available data bases, medical literature and the documented&#xD;
                  consensus of the Hematologic Malignancies Tumor Study Group&#xD;
&#xD;
          -  Patients must be an allogeneic HSCT candidate but have no standard donor (matched&#xD;
             related donor [MRD], human leukocyte antigen [HLA]-matched unrelated donor [MUD] or&#xD;
             single UCB unit of appropriate size and HLA type) available&#xD;
&#xD;
          -  Patients must have available UCB unit(s)&#xD;
&#xD;
          -  Patients considered for Arm 2 must not be eligible for Arm 1 and must have an&#xD;
             HLA-haploidentical sibling, parent, child, or other relative (uncle, aunt, first&#xD;
             cousin, niece or nephew) who meets donor requirements as outlined in Donor Eligibility&#xD;
             criteria&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =&lt;&#xD;
             2&#xD;
&#xD;
          -  Left ventricular (LV) ejection fraction &gt;= 50%&#xD;
&#xD;
          -  Diffusion capacity of carbon monoxide (DLCO) corrected for hemoglobin &gt; 60%&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits unless the patient has Gilbert's&#xD;
             disease&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =&lt;&#xD;
             2.5 X institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Measured or estimated creatinine clearance &gt; 50 ml/min&#xD;
&#xD;
          -  Hematopoietic stem cell co-morbidity index =&lt; 2&#xD;
&#xD;
          -  There must be a negative pregnancy test for women of childbearing potential within 1&#xD;
             week of therapy; there must be willingness to avoid pregnancy and undergo counseling&#xD;
             about contraceptive techniques throughout the course of treatment&#xD;
&#xD;
          -  There must be no uncontrolled infections or active acute or chronic illnesses such as&#xD;
             diabetes, angina/myocardial ischemia, cardiac arrhythmia, venous thrombosis/embolism,&#xD;
             cerebrovascular disease, seizure disorder, psychiatric illness or other intercurrent&#xD;
             illness that is not well controlled or is anticipated to be difficult to control&#xD;
             during the proposed therapy&#xD;
&#xD;
          -  The patient must be aware of the high risk and experimental nature of the treatment&#xD;
             and provide informed consent&#xD;
&#xD;
          -  The patient must have clearance for HSCT after psychosocial evaluation&#xD;
&#xD;
          -  The patient must have adequate insurance or other support to meet the anticipated&#xD;
             financial burden imposed by the costs of therapy&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): Relative (parent, child, sibling,&#xD;
             first cousin, uncle aunt, nephew, niece) with appropriate HLA match (&gt;= 3/6 HLA A, B,&#xD;
             DR match)&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): Age &gt;= 18 years old&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): Normal hemogram; potential donors not&#xD;
             having a normal hemogram may be utilized at the discretion of the Principal&#xD;
             Investigator&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): Not pregnant or lactating&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): Not human immunodeficiency virus&#xD;
             (HIV)-1, HIV-2, hepatitis C (HCV), Hepatitis B core or human T-lymphotropic virus&#xD;
             (HTLV)-I/II seropositive; hepatitis B surface antigen (HB Sag)(-); must meet other&#xD;
             infectious disease screening criteria utilized by New Brunswick Affiliated Hospital&#xD;
             (NBAH) Blood Center&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): No uncontrolled infections, other&#xD;
             medical or psychological/social conditions, or required medications that might&#xD;
             increase the likelihood of patient or donor adverse effects or poor outcomes&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): Meet other blood bank criteria for&#xD;
             blood product donation (as determined by NBAH Blood Center screening history)&#xD;
&#xD;
          -  DONOR (for allogeneic lymphocytes, Arm 2 only): Donors must be informed of the&#xD;
             investigational nature of this study, understand the requirements, potential benefits&#xD;
             and potential risks of the experimental treatment, and give written informed consent&#xD;
             in accordance with institutional and federal guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior extensive radiation therapy that the radiation oncologist feels precludes&#xD;
             additional TBI&#xD;
&#xD;
          -  Patients with known human immunodeficiency virus (HIV) are excluded due to side&#xD;
             effects of the therapy on the immune system&#xD;
&#xD;
          -  Patients with known active central nervous system (CNS) disease will be excluded from&#xD;
             this clinical trial because they often develop progressive neurologic dysfunction&#xD;
             unresponsive to HSCT therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Strair</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

